Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data

BACKGROUND: Intramuscular interferon beta-1a (IFNβ-1a), a multiple sclerosis (MS) therapy that has been commercially available for over a decade, provides a unique opportunity to retrospectively assess postmarketing data for evidence of malignancy risk, compared with relatively limited data availabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloomgren, Gary, Sperling, Bjørn, Cushing, Kimberly, Wenten, Madé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387830/
https://www.ncbi.nlm.nih.gov/pubmed/22767995
http://dx.doi.org/10.2147/TCRM.S31347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387830/
https://www.ncbi.nlm.nih.gov/pubmed/22767995
http://dx.doi.org/10.2147/TCRM.S31347

Ejemplares similares